References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailBrain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations.
CAVALIER, Etienne ULiege; CARLISI, Ignazia ULiege; KOVACS, Stéphanie ULiege et al

in Osteoporosis International (2016, April), 27(Supplement 1), 512

Detailed reference viewed: 35 (1 ULiège)
Full Text
Peer Reviewed
See detailEnglish translation and cross-cultural adaptation of the SarQuoL® questionnaire.
Beaudart, Charlotte ULiege; Edwards, M.; Dennison, E.M. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 221-222

Detailed reference viewed: 48 (4 ULiège)
Full Text
Peer Reviewed
See detailPhysical and muscle performances among elderly nursing home residents.
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; Croisier, Jean-Louis ULiege et al

in Osteoporosis International (2016, April), 27(Supplement 1), 217

Detailed reference viewed: 31 (3 ULiège)
Full Text
Peer Reviewed
See detailPrevalence of frailty among nursing home, according to different operational definitions.
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; GILLAIN, Sophie ULiege et al

in Osteoporosis International (2016, April), 27(Supplement 1), 216-217

Detailed reference viewed: 22 (3 ULiège)
Full Text
Peer Reviewed
See detailTen years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial.
Bone, H.G.; Brandi, M.L.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 135-136

Detailed reference viewed: 217 (1 ULiège)
Full Text
Peer Reviewed
See detailPrevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge study.
Locquet, Médéa ULiege; Beaudart, Charlotte ULiege; Reginster, Jean-Yves ULiege et al

in Osteoporosis International (2016, April), 27(supplement 1), 129

Detailed reference viewed: 37 (4 ULiège)
Full Text
Peer Reviewed
See detailEfficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Rannou, F.; Maheu; Reginster, Jean-Yves ULiege

in Osteoporosis International (2016, April), 27(supplement 1), 66

Detailed reference viewed: 18 (2 ULiège)
Full Text
Peer Reviewed
See detailEfficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Reginster, Jean-Yves ULiege

in Osteoporosis International (2016, April), 27(supplement 1), 65

Detailed reference viewed: 63 (0 ULiège)
Full Text
Peer Reviewed
See detailThe future prevalence of sarcopenia in Europe
Ethgen, Olivier ULiege; Tchoconte, C.; Beaudart, Charlotte ULiege et al

in Osteoporosis International (2016, April), 27(Supplement 1), 53-54

Detailed reference viewed: 75 (3 ULiège)
Full Text
Peer Reviewed
See detailrelationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment
Ferrari, S.; ADAMI, S.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 49-50

Detailed reference viewed: 44 (0 ULiège)
Full Text
Peer Reviewed
See detailA randomized double-blind study of Denosumab (DMAB) compared with Zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates
Miller, P.; Pannacciulli, N.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(SUPPLEMENT1), 42

Detailed reference viewed: 73 (0 ULiège)
Full Text
Peer Reviewed
See detailBalancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Cooper, C.; Bardin, T.; Brandi, M.L. et al

in Aging Clinical and Experimental Research (2016), 28(1), 1-16

Purpose: This consensus review article considers the question of whether glucocorticoid (GC) therapy is still relevant in the treatment of rheumatic diseases, with a particular focus on rheumatoid ... [more ▼]

Purpose: This consensus review article considers the question of whether glucocorticoid (GC) therapy is still relevant in the treatment of rheumatic diseases, with a particular focus on rheumatoid arthritis (RA), and whether its side effects can be adequately managed. Recent basic and clinical research on the molecular, cellular and clinical effects of GCs have considerably advanced our knowledge in this field. An overview of the subject seems appropriate. Methods: This review is the result of a multidisciplinary expert working group, organised by European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. The recent literature was surveyed and the salient evidence synthetized. Results: The pathophysiological basis of RA (and other inflammatory rheumatic diseases) now strongly implicates the adaptive immune system in addition to innate mechanisms. The molecular effect of GCs and differential GC sensitivity is better understood, although exploiting this knowledge is still in its infancy. The newer treatment strategies of early and aggressive control of RA have greatly improved clinical outcomes, but improvements are still possible. Newer targeted anti-inflammatory drugs have made an important impact, yet they too are associated with numerous side effects. Discussion: Short durations of moderate doses of GCs are generally well tolerated and have a positive benefit/risk ratio. Patients should be assessed for fracture risk and bone preserving agents and be prescribed calcium and vitamin D supplementation. Conclusions: Within a strategy of a disease modifying approach to inflammatory disease, combination therapy including a GC is effective approach. [less ▲]

Detailed reference viewed: 12 (1 ULiège)
Full Text
Peer Reviewed
See detailDiacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
Pavelka, Karel; Bruyère, Olivier ULiege; Cooper, Cyrus et al

in Drugs & Aging (2016), 33(2), 75-85

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been ... [more ▼]

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit–risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated [less ▲]

Detailed reference viewed: 30 (0 ULiège)
Full Text
Peer Reviewed
See detailOsteoporosis and sarcopenia: two diseases or one?
Reginster, Jean-Yves ULiege; Beaudart, Charlotte ULiege; Buckinx, Fanny ULiege et al

in Current Opinion in Clinical Nutrition & Metabolic Care (2016), 19(1), 31-6

Purpose of review This article reviews recently published evidence for common pathways explaining bone and muscle wasting in normal ageing and pathological conditions. Recent findings Numerous studies ... [more ▼]

Purpose of review This article reviews recently published evidence for common pathways explaining bone and muscle wasting in normal ageing and pathological conditions. Recent findings Numerous studies support the concept of a bone–muscle unit, where constant cross-talking between the two tissues takes place, involving molecules released by the skeletal muscle secretome, which affects bone, and osteokines secreted by the osteoblasts and osteocytes, which, in turn, impact muscle cells. Summary New chemical entities aiming at concomitantly treating osteoporosis and sarcopenia could be developed by targeting pathways that centrally regulate bone and muscle or emerging pathways that facilitate the communication between the two tissues. [less ▲]

Detailed reference viewed: 29 (3 ULiège)
Full Text
Peer Reviewed
See detailDeterminants of vitamin D supplementation prescription in nursing homes: a survey among general practitioners
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; Cavalier, Etienne ULiege et al

in Osteoporosis International (2016), 27

Abstract Summary A total of 119 GPs participated to a survey aimed to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Among the respondent GPs, 65 (54.6 ... [more ▼]

Abstract Summary A total of 119 GPs participated to a survey aimed to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Among the respondent GPs, 65 (54.6 %) systematically prescribe vitamin D to their institutionalized patients and the 54 (45.4 %) others prescribe only sometimes. Introduction The aim of this study is to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Methods General practitioners (GPs) having at least one patient in a nursing home in Liège, Belgium, were asked to complete the survey. Results A total of 119 GPs participated in the survey. Among the respondent GPs, 65 (54.6 %) systematically prescribe vitamin D to their institutionalized patients and the 54 (45.4 %) others prescribe only sometimes. The main reasons for prescribing vitamin D cited by GPs who do so systematically are as follows: because they believe nursing home residents are mostly deficient in vitamin D status (92.1 %), because they believe that vitamin D supplementation prevents osteoporotic fractures (77.8 %), and because vitamin D supplementation is recommended by various scientific societies (38.1 %). GPs who only prescribe vitamin D supplementation in some patients mainly do so following a diagnosis of osteoporosis (82.4 %), on the basis the 25(OH)D level (78.4 %), in the case of history of fracture (54.9 %) or after a recent fracture (43.4 %). Surprisingly, 16 physicians (31.4 %) only prescribe vitamin D when they think of it. Interestingly, while 40.7% of GPs always prescribe the same dose of vitamin D, the remaining 59.3 % prescribe a dose that will mainly depend on the results of the 25(OH)D level (94.0 %), the patient’s bone health (49.3 %), or history of fracture (43.3 %). Conclusions More than half of GPs systematically prescribe vitamin D to their patients living in nursing homes. The other GPs usually prescribe vitamin D following the result of the vitamin D status or after a diagnosis of osteoporosis. [less ▲]

Detailed reference viewed: 52 (15 ULiège)
Full Text
Peer Reviewed
See detailCost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures
Ethgen, Olivier ULiege; Hiligsmann, Mickaël; Burlet, Nansa et al

in Osteoporosis International (2016), 27

Summary: Titrated supplementations with vitamin D-fortified yogurt, based on spontaneous calcium and vitamin D intakes, can be cost-effective in postmenopausal women with or without increased risk of ... [more ▼]

Summary: Titrated supplementations with vitamin D-fortified yogurt, based on spontaneous calcium and vitamin D intakes, can be cost-effective in postmenopausal women with or without increased risk of osteoporotic fractures. Introduction: The objective of this study is to assess the costeffectiveness of the vitamin D-fortified yogurt given to women with and without an increased risk of osteoporotic fracture. Methods: Avalidated cost-effectiveness microsimulation Markov model of osteoporosis management was used. Three personalized supplementation scenarios to reflect the Ca/Vit D needs taking into account the well-known variations in dietary habits and a possible pharmacological supplementation in Ca/ Vit D, given above or in combination with anti-osteoporosis medications: one yogurt per day, i.e., 400 mg of Ca+200 IU of Vit D (scenario 1 U), two yogurts per day, i.e., 800 mg of Ca+ 400 IU of Vit D (scenario 2 U), or three yogurts per day, i.e., 1, 200 mg of Ca+600 IU of Vit D (scenario 3 U). Results: One yogurt is cost-effective in the general population above the age of 70 years and in all age groups in women with low bone mineral density (BMD) or prevalent vertebral fracture (PVF). The daily intake of two yogurts is cost-effective above 80 years in the general population and above 70 years in the two groups of women at increased risk of fractures. However, an intake of three yogurts per day is only cost-effective above 80 years old in the general population, as well as in women with low BMD or PVF. Conclusions: Our study is the first economic analysis supporting the cost-effectiveness of dairy products, fortified with vitamin D, in the armamentarium against osteoporotic fractures. [less ▲]

Detailed reference viewed: 22 (1 ULiège)
Full Text
Peer Reviewed
See detailInnovation for healthy ageing: A call for papers
de Carvalho, I. A.; Aboderin, I.; Arikawa-Hirasawa, E. et al

in Bulletin of the World Health Organization (2016), 94(6), 407-407

[No abstract available]

Detailed reference viewed: 23 (4 ULiège)
Full Text
Peer Reviewed
See detailCritical analytical evaluation of promising markers for sarcopenia
Cavalier, Etienne ULiege; Beaudart, Charlotte ULiege; Buckinx, Fanny ULiege et al

in European Geriatric Medicine (2016), 7(3), 239-242

We tested and validated irisin (IRI), myostatin (MYO), PIIINP, osteoglycin (OGN), TMEM119 (TMEM) and activin A (AA) and established the analytical performance, reference range and stability (considered ... [more ▼]

We tested and validated irisin (IRI), myostatin (MYO), PIIINP, osteoglycin (OGN), TMEM119 (TMEM) and activin A (AA) and established the analytical performance, reference range and stability (considered unstable if more than 20% increase/decrease in the levels was observed in more than 10% of the samples). We were unable to obtain a valuable calibration curve with the Cusabio kits (TMEME and OGN). Coefficient of variation (CV) was too high for IRI (CV 17-30%), but were ≤ 10% for the 3 other analytes. AA and MYO were stable up to 3 months at -20 °C and -80 °C in serum or EDTA plasma and up to 6 months at -80 8C. PIIINP was stable only 1 month in EDTA plasma (but not in serum) at -20 °C or -80 8C. After 3 months of storage, PIIINP was not stable anymore, in serum or EDTA plasma, at -20 °C or -80 8C. Surprisingly, after 6 months at -80 8C, results returned in the ± 20% for both serum and EDTA plasma. PIIINP levels did not differ between men and women and the RR was (median, 90% CI) 1.2 (0.8-1.6)-6.0 (5.6-6.4) μg/L. The RR for MYO was 845 (437-1312)-6067 (5524-6552) pg/mL for men and 600 (268-1027)-4438 (4026-4837) pg/mL for women and the RR for AA was 177 (132-210)-622 (580-661) pg/mL for men and 98 (49-147)-480 (430-525) pg/mL for women. PIIINP and AA but not MYO accumulated in CKD as values observed in 10 hemodialyzed patients were higher than in normal individuals. © 2015 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved. [less ▲]

Detailed reference viewed: 23 (0 ULiège)